AmgenCHIX:AMGD 90 EV-to-EBITDA is 14.81 as of Jul. 13, 2026, which is 18% above its 10-year median of 12.50. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 739 Drug Manufacturers companies, Amgen ranks worse than 54.13% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Amgen's enterprise value is €211,986 Mil.
Amgen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €14,315 Mil. Therefore, Amgen's EV-to-EBITDA for today is 14.81.
The historical rank and industry rank for Amgen's EV-to-EBITDA or its related term are showing as below:
CHIX:AMGd'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.21 Med: 12.5 Max: 19.97
Current: 14.48
During the past 13 years, the highest EV-to-EBITDA of Amgen was 19.97. The lowest was 8.21. And the median was 12.50.
CHIX:AMGd's EV-to-EBITDA is ranked worse than 54.13% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs CHIX:AMGd: 14.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-13), Amgen's stock price is €285.00.
Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €12.331. Therefore, Amgen's PE Ratio (TTM) for today is 23.11.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Amgen (CHIX:AMGd) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amgen's share price for today is €285.00.
Amgen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.331.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Amgen's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMGD vs GILD, PFE, BMY: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Amgen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amgen's EV-to-EBITDA falls into.
Amgen's current Enterprise Value is €211,986 Mil.
Amgen's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14,315 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (CHIX:AMGD) has a EV-to-EBITDA of 14.81 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Amgen. This is 18% above median its historical median of 12.50. Over the past decade, Amgen's EV-to-EBITDA has ranged from 8.21 to 19.97. According to the industry distribution chart, Amgen ranks #400 out of 739 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Amgen's EV-to-EBITDA too high?
Amgen's current EV-to-EBITDA of 14.81 is 18% above median its 10-year median of 12.50. Over the past 10 years, this metric has ranged from a low of 8.21 to a high of 19.97. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Amgen's value of 14.81 is 14.3% above this industry median. Based on the distribution chart, Amgen ranks #400 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's EV-to-EBITDA compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #400 out of 739 companies for EV-to-EBITDA. This places Amgen in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Amgen's value of 14.81 is 14.3% above this benchmark. Historically, Amgen's own EV-to-EBITDA has ranged from 8.21 to 19.97 over the past decade. While the company's 10-year median is 12.50 vs. the industry median of 12.96, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current EV-to-EBITDA of 14.81 is 14.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Amgen. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current EV-to-EBITDA is 14.81, which is 18% above median its own 10-year median of 12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current EV-to-EBITDA is 14.81, which is 18% above median its 10-year median of 12.50 and 14.3% above the Drug Manufacturers industry median of 12.96. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current EV-to-EBITDA is 14.81 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
EV-to-EBITDA: 14.81 (18% above median its 10-year median of 12.50)
GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
Industry Position: 14.3% above the Drug Manufacturers median (#400 of 739)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score
Get the complete analysis for CHIX:AMGD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
